دورية أكاديمية
أعرض في EDS

Sweet flowers are slow, and weeds make haste: leveraging methodology from research on tobacco, alcohol, and opioid analgesics to make rapid and policy-relevant advances in cannabis science.

التفاصيل البيبلوغرافية
العنوان: Sweet flowers are slow, and weeds make haste: leveraging methodology from research on tobacco, alcohol, and opioid analgesics to make rapid and policy-relevant advances in cannabis science.
المؤلفون: Herrmann ES; a Individual and Population Health, Battelle , Baltimore , MD , USA., Jarvis BP; a Individual and Population Health, Battelle , Baltimore , MD , USA., Sparks AC; a Individual and Population Health, Battelle , Baltimore , MD , USA., Cohn AM; a Individual and Population Health, Battelle , Baltimore , MD , USA., Koszowski B; a Individual and Population Health, Battelle , Baltimore , MD , USA., Rosenberry ZR; a Individual and Population Health, Battelle , Baltimore , MD , USA., Coleman-Cowger VH; a Individual and Population Health, Battelle , Baltimore , MD , USA., Pickworth WB; a Individual and Population Health, Battelle , Baltimore , MD , USA., Peters EN; a Individual and Population Health, Battelle , Baltimore , MD , USA.
المصدر: International review of psychiatry (Abingdon, England) [Int Rev Psychiatry] 2018 Jun; Vol. 30 (3), pp. 238-250.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Review
اللغة: English
بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918131 Publication Model: Print Cited Medium: Internet ISSN: 1369-1627 (Electronic) Linking ISSN: 09540261 NLM ISO Abbreviation: Int Rev Psychiatry Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Informa Healthcare
Original Publication: Abingdon, Oxfordshire, U.K. : Carfax Pub. Co., c1989-
مواضيع طبية MeSH: Alcoholic Beverages* , Analgesics, Opioid* , Biomedical Research* , Cannabis* , Legislation, Drug* , Public Health* , Tobacco Products*, Humans ; United States
مستخلص: The legalization of medical and recreational cannabis use has occurred ahead of science. The current evidence base has poor utility for determining if cannabis products can meet the standards of safety, efficacy, and quality intrinsic to modern medicine, and for informing regulation of cannabis as a legal intoxicant. Individual jurisdictions that pass cannabis reforms may not have adequate resources to support the level of new scientific research needed to inform regulatory actions; this could make it difficult to keep a rapidly growing multi-billion-dollar cannabis industry in check. Further, the present lack of evidence-based regulatory oversight for cannabis parallels the climates that gave rise to the tobacco and prescription opioid epidemics, suggesting that continued omission may result in negative public health consequences. However, translating a methodological framework developed through research on these compounds may promote rapid advances in cannabis science germane to regulatory knowledge gaps. The present review highlights specific advancements in these areas, as well as in alcohol regulation, that are prime for informing policy-relevant cannabis science, and also offers some recommendations for evidence-based regulatory policy. Resulting progress may directly inform both regulation of cannabis in both medical and licit recreational drug frameworks, and new cannabis-related public health initiatives.
References: Drug Alcohol Depend. 2017 Jun 1;175:36-41. (PMID: 28380366)
JAMA. 2015 Jun 23-30;313(24):2491-3. (PMID: 26103034)
Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. (PMID: 18606504)
Addiction. 2012 Mar;107(3):478-85. (PMID: 22313102)
Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S14-25. (PMID: 19443137)
Alcohol Alcohol. 2009 May-Jun;44(3):229-43. (PMID: 19144976)
Pediatrics. 2007 Jan;119(1):76-85. (PMID: 17200273)
Drug Alcohol Depend. 2017 Nov 1;180:151-155. (PMID: 28892720)
Am J Prev Med. 2009 Dec;37(6):556-69. (PMID: 19944925)
Neuropsychopharmacology. 2015 Oct;40(11):2489-98. (PMID: 25881117)
J Opioid Manag. 2015 May-Jun;11(3):199-210. (PMID: 25985805)
Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3241-62. (PMID: 19959676)
Neuropsychopharmacology. 2013 Jul;38(8):1557-65. (PMID: 23443718)
Drug Alcohol Depend. 2017 Aug 1;177:1-13. (PMID: 28549263)
Nebr Symp Motiv. 2009;55:91-109. (PMID: 19013940)
Am J Prev Med. 2010 Feb;38(2):217-29. (PMID: 20117579)
Cannabis Cannabinoid Res. 2017 Jun 01;2(1):105-113. (PMID: 28861510)
Neuropsychopharmacology. 2016 Jul;41(8):1974-82. (PMID: 26708108)
Drug Alcohol Depend. 2007 Jan 5;86(1):22-9. (PMID: 16769180)
Prev Med. 2017 Nov;104:4-6. (PMID: 28232101)
J Consult Clin Psychol. 1993 Oct;61(5):743-50. (PMID: 8245272)
Annu Rev Public Health. 2015 Mar 18;36:559-74. (PMID: 25581144)
Psychopharmacology (Berl). 1978 Jun 15;58(1):35-41. (PMID: 97717)
Health Educ Res. 2017 Dec 1;32(6):465-472. (PMID: 29237032)
Drug Alcohol Rev. 2018 Apr;37 Suppl 1:S203-S205. (PMID: 29024092)
Lancet Psychiatry. 2016 Sep;3(9):900-6. (PMID: 27374072)
Science. 1999 Jan 15;283(5400):401-4. (PMID: 9888857)
JAMA Intern Med. 2018 Jan 1;178(1):9-10. (PMID: 29159413)
Am J Public Health. 2018 Jan;108(1):19-21. (PMID: 29211540)
Am J Epidemiol. 2014 Feb 1;179(3):299-302. (PMID: 24355333)
CNS Neurosci Ther. 2015 Mar;21(3):215-21. (PMID: 25475413)
Annu Rev Public Health. 2003;24:267-88. (PMID: 12415145)
Neuropsychopharmacology. 2006 Oct;31(10):2296-303. (PMID: 16572123)
J Pharmacol Exp Ther. 1992 Apr;261(1):114-22. (PMID: 1313866)
Am J Psychiatry. 2004 Nov;161(11):1967-77. (PMID: 15514394)
Cannabis Cannabinoid Res. 2016 Dec 01;1(1):244-251. (PMID: 28861496)
JAMA. 2017 Nov 7;318(17):1708-1709. (PMID: 29114823)
Brain Res. 1999 Nov 27;848(1-2):183-90. (PMID: 10612710)
Addict Biol. 2015 Mar;20(2):357-67. (PMID: 24373053)
J Anal Toxicol. 2013 Jan-Feb;37(1):11-6. (PMID: 23074216)
Curr Top Behav Neurosci. 2017;34:33-58. (PMID: 27356522)
Psychol Addict Behav. 2015 Sep;29(3):613-9. (PMID: 26030167)
J Public Health Policy. 2005 Sep;26(3):343-58. (PMID: 16167561)
Am J Prev Med. 2010 Dec;39(6):590-604. (PMID: 21084080)
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49. (PMID: 26987082)
Addiction. 2016 Oct;111(10):1764-73. (PMID: 27082374)
PLoS One. 2015 Aug 26;10(8):e0133292. (PMID: 26308334)
Eval Rev. 1997 Apr;21(2):246-67. (PMID: 10183277)
Harm Reduct J. 2015 Oct 14;12:46. (PMID: 26467203)
CMAJ. 2016 Dec 6;188(17-18):1240-1244. (PMID: 27821465)
Biol Psychiatry. 2016 Apr 1;79(7):613-9. (PMID: 26903403)
Drug Alcohol Depend. 2017 May 1;174:192-200. (PMID: 28365173)
Prev Chronic Dis. 2013 Apr 11;10:E53. (PMID: 23578401)
Int J Environ Res Public Health. 2011 Feb;8(2):613-28. (PMID: 21556207)
BMC Health Serv Res. 2017 Jun 20;17(1):420. (PMID: 28633638)
Neuropsychopharmacology. 2018 Sep;43(10):2046-2055. (PMID: 29463913)
Psychopharmacology (Berl). 2007 Nov;194(4):505-15. (PMID: 17619859)
Am J Public Health. 2018 Jan;108(1):120-127. (PMID: 29161062)
Alcohol Res Health. 2002;26(1):22-34. (PMID: 12154648)
Addiction. 2012 Aug;107(8):1493-500. (PMID: 22229871)
EMBO Rep. 2015 Feb;16(2):130-2. (PMID: 25576303)
Front Pharmacol. 2016 Sep 30;7:359. (PMID: 27746737)
Health Econ. 2006 Jun;15(6):617-37. (PMID: 16475245)
معلومات مُعتمدة: R01 AA024709 United States AA NIAAA NIH HHS
فهرسة مساهمة: Keywords: Cannabis; behaviour; legalization; medicine; policy
المشرفين على المادة: 0 (Analgesics, Opioid)
تواريخ الأحداث: Date Created: 20180905 Date Completed: 20190321 Latest Revision: 20240714
رمز التحديث: 20240714
مُعرف محوري في PubMed: PMC6396691
DOI: 10.1080/09540261.2018.1465400
PMID: 30179535
قاعدة البيانات: MEDLINE
الوصف
تدمد:1369-1627
DOI:10.1080/09540261.2018.1465400